June 17, 2020 / 12:06 PM / a month ago

BRIEF-Viralclear Doses First Patient In Phase II Human Trial Of Anti-Viral MMPD Oral Solution For Treatment Of Covid-19

June 17 (Reuters) - Biosig Technologies Inc:

* VIRALCLEAR OPENS ENROLLMENT WITH FIRST PATIENT DOSING IN PHASE II HUMAN TRIAL OF ANTI-VIRAL MMPD ORAL SOLUTION FOR TREATMENT OF COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below